Abstracts

ADVANCES IN HIV PREVENTION

During the Program Committee Workshop for New Investigators and Trainees, Dr. Susan Buchbinder reviewed the current status of new infections globally, and discussed recent advances in biomedical HIV-1 prevention including treatment as prevention, pre-exposure prophylaxis, topical preventive agents, HIV vaccines, and combination approaches to HIV prevention.

ADVANCES IN HIV CURE

During the Program Committee Workshop for New Investigators and Trainees, Dr. Nicolas Chomont reviewed the mechanisms that contribute to HIV persistence during ART, highlighted the role of cell proliferation in that process and presented recent therapeutic approaches aimed at curing HIV infection

VIROLOGY OF CORONAVIRUSES

In a special session, speakers presented state-of-the-art of what is known about the 2019-novel coronavirus (COVID-19) outbreak and its causative pathogen, SARS-CoV-2. Dr Ralph Baric focused on the virology of coronaviruses overall, molecular aspects of transmission to humans, and pathogenesis in mice models and parallels in humans.

US RESPONSE TO COVID 19

In a special session, speakers presented state-of-the-art of what is known about the 2019-novel coronavirus (COVID-19) outbreak and its causative pathogen, SARS-CoV-2. Dr Anthony Fauci described efforts by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health to study novel coronaviruses and develop diagnostics, therapeutics, and vaccines.

INTRODUCTION OF HVTN 702 STUDY

On February 3, 2020 the HVTN 702 HIV vaccine efficacy trial in South Africa discontinued vaccinations because the interim review by the Data and Safety Monitoring Board reported that the vaccine candidate did not prevent HIV. There were no safety concerns. Dr Lawrence Corey provided a brief overview of the HVTN 702 Study.

ADVANCES IN HIV IMMUNOLOGY AND VACCINES

During the Program Committee Workshop for New Investigators and Trainees, Dr. Richard Koup reviewed recent preclinical HIV vaccine advances, concentrating on efforts to induce either broad neutralizing antibody responses or protective CD8 T cells, and discussed the latest data on the development and use of broadly neutralizing antibodies in prevention and treatment of HIV.

IL-6 AND D-DIMER PREDICT MORTALITY AND ARE ELEVATED AFTER DELAYED HIV TREATMENT

In HIV-infected individuals nonspecific inflammation is associated with disease progression and increased mortality. The effect of the timing of antiretroviral therapy (ART) in mitigating inflammation at lower CD4 counts is still unclear. We investigated longitudinal trends in C-reactive protein (CRP), interleukin (IL)-6 and D-dimer following delayed ART initiation and identified predictors of mortality. CIPRA HT001…